237 related articles for article (PubMed ID: 38137845)
1. Examining the Safety Profile of Janus Kinase (JAK) Inhibitors in the Management of Immune-Mediated Diseases: A Comprehensive Review.
Kraev K; Geneva-Popova MG; Hristov BK; Uchikov PA; Belova-Popova SD; Kraeva MI; Basheva-Kraeva YM; Stoyanova NS; Mitkova-Hristova VT; Koleva-Ivanova MS; Taneva DI; Ivanov AS
Life (Basel); 2023 Nov; 13(12):. PubMed ID: 38137845
[TBL] [Abstract][Full Text] [Related]
2. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott IC; Hider SL; Scott DL
Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
[TBL] [Abstract][Full Text] [Related]
3. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
4. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
5. The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions.
Fragoulis GE; Brock J; Basu N; McInnes IB; Siebert S
J Allergy Clin Immunol; 2021 Oct; 148(4):941-952. PubMed ID: 34450118
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis.
Wei Q; Wang H; Zhao J; Luo Z; Wang C; Zhu C; Su N; Zhang S
Front Pharmacol; 2023; 14():1237234. PubMed ID: 37614310
[No Abstract] [Full Text] [Related]
7. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
Núñez P; Quera R; Yarur AJ
Drugs; 2023 Mar; 83(4):299-314. PubMed ID: 36913180
[TBL] [Abstract][Full Text] [Related]
8. Dermatologic Applications and Safety Considerations of Janus Kinase Inhibitors.
Svoboda SA; Johnson N; Phillips M
Skin Therapy Lett; 2020 Sep; 25(4):6-11. PubMed ID: 33017108
[TBL] [Abstract][Full Text] [Related]
9. Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis.
Zhang J; Li W; Gong M; Gu Y; Zhang H; Dong B; Guo Q; Pang X; Xiang Q; He X; Cui Y
Front Pharmacol; 2023; 14():1189389. PubMed ID: 37351513
[No Abstract] [Full Text] [Related]
10. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis.
Harigai M
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i34-i42. PubMed ID: 30806708
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
[TBL] [Abstract][Full Text] [Related]
12. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
Kotyla PJ; Islam MA; Engelmann M
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036382
[TBL] [Abstract][Full Text] [Related]
13. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.
Nezamololama N; Fieldhouse K; Metzger K; Gooderham M
Drugs Context; 2020; 9():. PubMed ID: 33240390
[TBL] [Abstract][Full Text] [Related]
14. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
15. Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications.
Shalabi MMK; Garcia B; Coleman K; Siller A; Miller AC; Tyring SK
Skin Therapy Lett; 2022 Jan; 27(1):4-9. PubMed ID: 35081305
[TBL] [Abstract][Full Text] [Related]
16. Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome.
Tanaka Y
Expert Opin Pharmacother; 2023; 24(16):1791-1798. PubMed ID: 37563102
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
18. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Iwata S; Tanaka Y
Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials.
Maqsood MH; Weber BN; Haberman RH; Lo Sicco KI; Bangalore S; Garshick MS
ACR Open Rheumatol; 2022 Oct; 4(10):912-922. PubMed ID: 35903881
[TBL] [Abstract][Full Text] [Related]
20. Chemical JAK inhibitors for the treatment of rheumatoid arthritis.
Nakayamada S; Kubo S; Iwata S; Tanaka Y
Expert Opin Pharmacother; 2016 Nov; 17(16):2215-2225. PubMed ID: 27690665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
